{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:50:27Z","timestamp":1721317827039},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T00:00:00Z","timestamp":1444348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The early persistence of minimal residual disease (MRD) is considered a poor prognostic factor indicative of chemoresistance in acute lymphoblastic leukemia. In French children, chemosensitivity is assessed at day 21 post\u2010induction by cytomorphology. Here, it was investigated whether a more precise evaluation could be obtained at this time point with multiparameter flow cytometry (MFC).<\/jats:p><jats:p>This study enrolled 123 children with <jats:italic>de novo<\/jats:italic> acute lymphoblastic leukemia. MRD0 was investigated at day 21 in MFC with a combination of antibodies based on the immunophenotype of diagnosis. It was also evaluated at day 35 by immunoglobulin\/T\u2010cell receptor quantitative real\u2010time polymerase chain reaction (MRD1).<\/jats:p><jats:p>Three risk groups could be delineated based on MRD0. Patients with MFC\/MRD0 levels &gt;10<jats:sup>\u22122<\/jats:sup> (<jats:italic>n<\/jats:italic>\u2009=\u200925) were considered high risk, those with levels between 10<jats:sup>\u22122<\/jats:sup> and 10<jats:sup>\u22124<\/jats:sup> (<jats:italic>n<\/jats:italic>\u2009=\u200946) intermediate risk, and those &lt;10<jats:sup>\u22124<\/jats:sup> (<jats:italic>n<\/jats:italic>\u2009=\u200950) low risk. Overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.048) and event\u2010free survival (EFS, <jats:italic>p<\/jats:italic>\u2009=\u20090.00017) were significantly different between these three groups. EFS of the 14 corticoresistant patients strongly depended on their MRD0 level (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). Similarly, both EFS (p\u2009=\u20090.0004) and overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) were significantly different in the 109 chemosensitive patients, according to MRD0 levels. MRD0 and MRD1 levels, compared with 112 patients, were consistent (\u2212\/\u2212 or +\/+) in 57.2% of the cases. Both MRD0+\/MRD1+ and MRD0+\/MRD1\u2212 patients had a significantly worse EFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001) than those with undetectable MRD at both MRD0 and MRD1.<\/jats:p><jats:p>This study confirms the usefulness and superiority of an early point of MRD detection by MFC. In addition, MRD0 in MFC identifies a subgroup of patients with poorer prognosis (MRD0+\/MRD1\u2212). Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2263","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T08:02:46Z","timestamp":1444377766000},"page":"237-243","source":"Crossref","is-referenced-by-count":3,"title":["Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"35","author":[{"given":"Marion","family":"Eveillard","sequence":"first","affiliation":[{"name":"Hematology Biology Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Robillard","sequence":"additional","affiliation":[{"name":"Hematology Biology Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Arnoux","sequence":"additional","affiliation":[{"name":"Hematology Biology Timone University Hospital  Marseilles France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Garand","sequence":"additional","affiliation":[{"name":"Hematology Biology Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[{"name":"Oncopediatrics Department Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Thomas","sequence":"additional","affiliation":[{"name":"Oncopediatrics Department Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Strullu","sequence":"additional","affiliation":[{"name":"Oncopediatrics Department Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Michel","sequence":"additional","affiliation":[{"name":"Oncopediatrics Department Timone University Hospital  Marseilles France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie C.","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[{"name":"Hematology Biology Nantes University Hospital  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Fossat","sequence":"additional","affiliation":[{"name":"Hematology Biology Timone University Hospital  Marseilles France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Loosveld","sequence":"additional","affiliation":[{"name":"Hematology Biology Timone University Hospital  Marseilles France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-024729"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3283543d5c"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.11.009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.234"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.060426"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cytob.21195","article-title":"French Multicenter Study Groups for Pediatric and Adult ALL. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: a French multicenter study","volume":"88","author":"Fossat C1","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-4079(19)34595-9"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.246"},{"key":"e_1_2_7_15_1","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene MC","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70066-8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13405"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8934"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.558"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.010"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24299"},{"key":"e_1_2_7_23_1","article-title":"T\u2010lymphoblastic leukemia (T\u2010ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype and validation of the prognostic value of end\u2010induction minimal residual disease (MRD) in Children's Oncology Group (COG) study AALL0434","author":"Wood B","year":"2014","journal-title":"Blood"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091819"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.186"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.296"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2263","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:12:23Z","timestamp":1694686343000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/hon.2263"],"URL":"https:\/\/doi.org\/10.1002\/hon.2263","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,9]]}}}